Maziar Mike Doustdar
President and Chief Executive Officer, Novo Nordisk · since 2025
In the news
Novo shares fall as much as 9% as investors question pricing power and deals
Novo shares fell as much as 9% intraday on 21 September 2026 and were down about 4.4% by midday in Copenhagen after recovering some losses.
News
CagriSema beats tirzepatide 5 mg on weight in REIMAGINE 5 and 21% weight loss in REDEFINE 9
Novo reported topline phase 3 results for CagriSema on 21 September 2026.
Project
Novo Nordisk reverses a USD 4.2 billion 340B provision, excluded from adjusted results
Novo Nordisk reversed a provision of USD 4.2 billion linked to the US 340B Drug Pricing Program, recorded in the first quarter of 2026.
Legal